Bentracimab
Intravenous infusion | |
---|---|
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
CAS Number | |
PubChem SID | |
DrugBank | |
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C2095H3240N560O674S12 |
Molar mass | 47440.93 g·mol−1 |
Bentracimab is a
clinical trials to function as a reversal agent for the anti–blood clotting drug ticagrelor (which acts as a P2Y12 inhibitor and is sold under the brand name Brilinta among others).[2] It is under investigation for use in major, life-threatening bleeding in patients being treated with ticagrelor.[3][4]
It is not commercially available.
See also
- Other reversal agents for antithrombotic drugs
References
- ^ "Specialist Pharmacy Service: Bentracimab". National Health Service. 10 January 2021.
- ^ "EU patients enrolled in REVERSE-IT trial of bentracimab for reversal of antiplatelet effects of ticagrelor". Cardiovascular News. 2021-01-29.
- ^ Clinical trial number NCT04286438 for "A Phase 3, Multicenter, Open-Label, Single-Arm Study of Bentracimab (PB2452) in Ticagrelor-Treated Patients With Uncontrolled Major or Life-Threatening Bleeding or Requiring Urgent Surgery or Invasive Procedure (REVERSE-IT Trial)" at ClinicalTrials.gov
- PMID 34028081.